PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment

@article{Devos2020PREDICTPA,
  title={PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment},
  author={Ga{\"e}tan Devos and Steven Joniau},
  journal={BMC Medicine},
  year={2020},
  volume={18}
}
Background Risk stratification tools are useful to optimize treatment decisions in each individual patient, reducing both underand overtreatment. Currently, several such tools are available to estimate disease aggressiveness in patients with localized prostate cancer (PCa). These include nomograms (e.g., Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram), tiered classification systems (e.g., D’Amico, National Comprehensive Cancer Network (NCCN)), and risk assessment scoring systems (e.g… 

Prostate cancer in omics era

TLDR
This review reports current findings and highlights a number of studies that are both novel and groundbreaking in their application of multi Omics to prostate cancer.

References

SHOWING 1-10 OF 15 REFERENCES

Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe)

TLDR
The discrimination of PREDICT Prostate significantly outperformed the EAU, NCCN and CAPRA scores for both PCSM and ACM within this cohort overall and demonstrates that PREDCT Prostate is a robust and generalisable model to aid clinical decision-making.

Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model

TLDR
An individualised prognostic model that contextualises PCa-specific mortality (PCSM) against other cause mortality, and estimates the impact of treatment on survival, and is the first to the authors' knowledge that models potential treatment benefits on overall survival.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

TLDR
A commercially available genomic classifier in combination with standard clinicopathologic variables can generate a simple-to-use clinical-genomic risk grouping that more accurately identifies patients at low, intermediate, and high risk for metastasis and can be easily incorporated into current guidelines to better risk-stratify patients.

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

TLDR
At a median of 10 years, prostate-cancer-specific mortality was low irrespective of the treatment assigned, with no significant difference among treatments.

Publisher's Note